Fewer than a tenth of individuals that would benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it releases its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Per forecasts, more than two billion could be living with obesity by 2030 without intervention.
"The new guidance recognises that obesity is a long-term condition that can be treated with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to broad availability to the treatments that can aid individuals in losing considerable weight, says the body.
Weight-Loss Drug Shortage
Even in the present most favorable scenario, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation urges countries and companies to widen availability, by approaches such as licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Work
The injections mimick a biological compound to slow digestion, suppress the appetite and increase the sense of being full so people reduce food intake.
Individuals usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Studies indicates patients may see weight return a year later of discontinuing the medication, as their typical hunger resume.
Being above a healthy weight raises your risk for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in all nations and was associated with millions of fatalities worldwide in 2024, per the WHO.
